Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Biliary Tract Neoplasms 2Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Malignant Neoplasms of Digestive Organs 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Advanced Biliary Tract Carcinoma 1

Interventions

Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Radiosurgery 2Liver Transplantation 2Gemcitabine 2Cisplatin 2Biopsy 2tislelizumab 1sacituzumab govitecan 1gemcitabine-oxaliplatin regimen 1fludarabine 1dehydroftorafur 1binimetinib 1Tegafur 1S 1 (combination) 1Pancreatic Hormones 1Leucovorin 1Hydroxychloroquine 1Cyclophosphamide 1Cholangiopancreatography, Endoscopic Retrograde 1Capecitabine 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Klatskin Tumor × Tegafur × 1 year × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡